Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
| Revenue (Most Recent Fiscal Year) | $85.16B |
| Net Income (Most Recent Fiscal Year) | $35.15B |
| PE Ratio (Current Year Earnings Estimate) | 14.42 |
| PE Ratio (Trailing 12 Months) | 14.00 |
| PEG Ratio (Long Term Growth Estimate) | 2.47 |
| Price to Sales Ratio (Trailing 12 Months) | 3.94 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.92 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 10.49 |
| Pre-Tax Margin (Trailing 12 Months) | 20.10% |
| Net Margin (Trailing 12 Months) | 19.14% |
| Return on Equity (Trailing 12 Months) | 35.45% |
| Return on Assets (Trailing 12 Months) | 14.23% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.03 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.79 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.45 |
| Inventory Turnover (Trailing 12 Months) | 2.29 |
| Book Value per Share (Most Recent Fiscal Quarter) | $28.57 |
| Earnings per Share (Most Recent Fiscal Quarter) | $2.42 |
| Earnings per Share (Most Recent Fiscal Year) | $9.92 |
| Diluted Earnings per Share (Trailing 12 Months) | $6.91 |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Common Shares Outstanding | 2.41B |
| Free Float | 2.40B |
| Market Capitalization | $345.11B |
| Average Volume (Last 20 Days) | 8.25M |
| Beta (Past 60 Months) | 0.51 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.16% |
| Percentage Held By Institutions (Latest 13F Reports) | 69.55% |
| Annual Dividend (Based on Last Quarter) | $4.96 |
| Dividend Yield (Based on Last Quarter) | 3.46% |